Please assess the completion status of the following clinical trial:

Trial Title: Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women = or \> 35 years of age presenting to the hospital with hyperglycemia (plasma glucose \>140 mg/dL) and Primary Anterior wall ST-Elevation Myocardial Infarction (AW STEMI)~* No history of illicit drug abuse in past year~* A minimum of 30 minutes but \< or = 6 hours of continuous pain/symptoms immediately prior to presentation~* Subjects who will undergo primary percutaneous coronary intervention (PCI)~* At least 2 contiguous precordial leads demonstrating at least 2 mm of ST-segment elevation consistent with anterior wall MI~* Signed informed consent and HIPAA documentation (US only) prior to participation in the study~* Subjects ability and willingness to adhere to and be compliant with study protocol~Exclusion Criteria:~* A prior history of Myocardial Infarction (MI)~* Subjects who have received any thrombolytic therapy during the current hospital admission~* Severe Heart Failure or cardiogenic shock (Killip class 3 or 4) by history or present at the time of screening~* Subjects with a plasma glucose \>400 mg/dL or diabetic ketoacidosis (DKA)~* History of Type 1 diabetes~* Active bleeding~* Active malignancy, chronic or other medical conditions likely to result in death over the next one year~* Recent hypotension requiring inotropic support in the past 30 days~* Participation in another clinical research study in the past 30 days~* Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method)~* Unwilling to give informed consent~* Subjects directly involved in the conduct of the study~* Known hypersensitivity to insulin glargine or glulisine~* Contraindication to MRI: a)Intracranial aneurysm clips (Unless the investigator is certain that it is made of non-ferromagnetic material such as titanium)b)Intra-orbital metal fragments c)Any electrically, magnetically or mechanically activated implants (including cardiac pacemakers, biostimulators, neurostimulators, cochlear implants, and hearing aids) d)Warning about Gadolinium-based contrast agents (GBCAs) Exposure to GBCAs increases the risk for nephrogenic systemic fibrosis (NSF). Therefore the following subjects should be excluded from the trial based on a history and/or laboratory tests:~  * acute or chronic severe renal insufficiency (glomerular filtration rate \<30 mL/min/1.73m2), as calculated by the MDRD (Modification of diet in Renal Disease) equation, or~ * acute renal insufficiency of any severity~* Subjects with blood pressure \> or = to 200/110 mmHg at time of randomization~* Subjects with a high degree of non-transient AV (Atrio-Ventricular) block~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intensive Insulin Therapy (IIT) (Type: ACTIVE_COMPARATOR): In IIT arm, subjects received intravenous (IV) insulin glulisine and subcutaneous (sc) insulin glargine to maintain a Blood Glucose (BG) concentration between 90-130 mg/dL.
- Standard Glycemic Care (SGC) (Type: ACTIVE_COMPARATOR): In SGC arm subjects assigned to standard of care received subcutaneous regular insulin per sliding scale.

Based on this trial design, predict the completion outcome and termination type (if applicable).